Cargando…

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Detalles Bibliográficos
Autores principales:	Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061291/ https://www.ncbi.nlm.nih.gov/pubmed/35210530 http://dx.doi.org/10.1038/s41375-022-01528-x

Ejemplares similares

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA
por: Gisslinger, Heinz, et al.
Publicado: (2023)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
por: Them, Nicole CC, et al.
Publicado: (2015)

Current and future treatment options for polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2015)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA
por: Kirito, K., et al.
Publicado: (2022)

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
por: Jin, Jie, et al.
Publicado: (2023)

P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY
por: Lee, Sung-Eun, et al.
Publicado: (2023)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
por: Pasi, K. John, et al.
Publicado: (2021)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

rs779805 Von Hippel-Lindau Gene Polymorphism Induced/Related Polycythemia Entity, Clinical Features, Cancer Association, and Familiar Characteristics
por: Remenyi, Gyula, et al.
Publicado: (2021)

Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
por: Sakatoku, Kazuki, et al.
Publicado: (2022)

Acute oxygenator occlusion in two cases of polycythemia vera: Bailout strategies
por: Kaiser, Philipp, et al.
Publicado: (2020)

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
por: Zhu, Min, et al.
Publicado: (2021)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Relative Polycythemia—The Polycythemia of Stress
por: Lawrence, John H., et al.
Publicado: (1952)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
por: Tefferi, A, et al.
Publicado: (2013)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021)

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
por: Chen, Kuan-Yuan, et al.
Publicado: (2021)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
por: Sørensen, Anders Lindholm, et al.
Publicado: (2016)

Allelic imbalance in CALR somatic mutagenesis
por: Harutyunyan, A S, et al.
Publicado: (2015)

Polycythemia and chorea
por: Ahmad, Feroze, et al.
Publicado: (2009)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.
por: Hoffman, Ronald, et al.
Publicado: (2023)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
por: Ianotto, Jean-Christophe, et al.
Publicado: (2019)

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
por: Gotic, Mirjana, et al.
Publicado: (2020)

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans
por: Kornienko, Aleksandra E., et al.
Publicado: (2016)

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
por: Qin, Albert, et al.
Publicado: (2023)

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
por: Brusson, Mégane, et al.
Publicado: (2018)

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial
por: Gisslinger, Heinz, et al.
Publicado: (2019)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i858qr28k933tcg4ls4jo0f753